应用自体肿瘤免疫细胞治疗中晚期肿瘤的意义

目的探讨树突状细胞（dendriticcells，DCs）和细胞因子诱导的杀伤细胞（cytokineinducedkil—let，CIK）联合化疗治疗晚期实体瘤的临床意义。方法采用自体肿瘤免疫细胞治疗晚期实体瘤患者130例。分离外周血单个核细胞，其中贴壁细胞用粒细胞巨噬细胞集落刺激因子、肿瘤坏死因子及白细胞介素4等诱导产生DCs，并用自体肿瘤细胞或外源性肿瘤细胞抗原致敏，获得Ag．DCs；悬浮细胞经干扰素-γ，IL2和CD3单克隆抗体（CD3 monoclonal antibody，CD3mAb）等诱导产生CIK细胞，将DCs与CIK细胞共同培养；采用FCM法检测DCs及CIK细胞表型，一次回输患者。结果130例中晚期肿瘤自体肿瘤免疫细胞联合化疗治疗后，完全缓解（CR）5例，部分缓解（PR）19例，稳定（SD）87例，疾病进展（PD）13例，6例晚期肿瘤进展死亡，疾病控制率85．38％。结论DCs—CIK细胞联合化疗治疗中晚期恶性实体瘤安全有效，具有重要的临床意义和应用前景。

Clinical significance of adoptive immunotherapy of cytokine-induced killer cells on the patients with advanced malignant tumors

Objective To study the clinical significance of the dendritic cells （DCs）and cytokine induced killer cell（CIK） in treating advanced malignant tumors. Methods From March 2010 to September 2011, peripheral blood mononuclear cells （PBMCs） of 130 patients with advanced malignant tumors were isolated, and then were incubated in vitro with IFN-γ, IL- 2 and anti- CD3 monoclonal antibody. The total number of DCs -CIK cells per patient expanded, and then were transfused back to the patients with one time. The changes of tumor weight, clinical symptoms, and toxicity in the patients were observed before and after DCs -CIK cells being transfused back. Results After treatment, complete remission （CR） was achieved in 5 patients, partial remission （PR） in 19 patients, stable disease （SD） in 87 patients,progressive disease （PD） in 13 patients,6 patients died. Conclusion Adoptive immunotherapy with DCs -CIK cells is safe, effective, probably which provide a new strategy for the patients with advanced malignant tumors.